Hypertension and COVID-19: Potential use of beta-blockers and a call for randomized evidence

Hypertension is one of the most common morbidities in COVID-19. Previous studies demonstrated that hypertension increases composite poor outcomes in patients with COVID-19. Beta-blockers is widely used as one of the most common antihypertensive agents. Beta-blockers may hold potential benefits in CO...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mochamad Yusuf Alsagaff, Eka Prasetya Budi Mulia
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	COVID-19 ACE2 Hypertension Adrenergic Beta-blocker Surgery RD1-811 Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/052af62d733549f38d2a5ef5588abc55
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:052af62d733549f38d2a5ef5588abc55
record_format	dspace
spelling	oai:doaj.org-article:052af62d733549f38d2a5ef5588abc552021-12-02T04:58:03ZHypertension and COVID-19: Potential use of beta-blockers and a call for randomized evidence0019-483210.1016/j.ihj.2021.10.011https://doaj.org/article/052af62d733549f38d2a5ef5588abc552021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S0019483221002303https://doaj.org/toc/0019-4832Hypertension is one of the most common morbidities in COVID-19. Previous studies demonstrated that hypertension increases composite poor outcomes in patients with COVID-19. Beta-blockers is widely used as one of the most common antihypertensive agents. Beta-blockers may hold potential benefits in COVID-19 treatment, with current evidence of the potential mechanism of beta-blockers remains scarce. However, several mechanisms were suggested, including decreasing RAAS pathway activity and lowering the ACE2 levels, reducing cytokine storms, and may be beneficial in reducing mortality in ARDS related COVID-19. Further large-scale randomized clinical trials should be conducted before a definite recommendation can be drawn.Mochamad Yusuf AlsagaffEka Prasetya Budi MuliaElsevierarticleCOVID-19ACE2HypertensionAdrenergicBeta-blockerSurgeryRD1-811Diseases of the circulatory (Cardiovascular) systemRC666-701ENIndian Heart Journal, Vol 73, Iss 6, Pp 757-759 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 ACE2 Hypertension Adrenergic Beta-blocker Surgery RD1-811 Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	COVID-19 ACE2 Hypertension Adrenergic Beta-blocker Surgery RD1-811 Diseases of the circulatory (Cardiovascular) system RC666-701 Mochamad Yusuf Alsagaff Eka Prasetya Budi Mulia Hypertension and COVID-19: Potential use of beta-blockers and a call for randomized evidence
description	Hypertension is one of the most common morbidities in COVID-19. Previous studies demonstrated that hypertension increases composite poor outcomes in patients with COVID-19. Beta-blockers is widely used as one of the most common antihypertensive agents. Beta-blockers may hold potential benefits in COVID-19 treatment, with current evidence of the potential mechanism of beta-blockers remains scarce. However, several mechanisms were suggested, including decreasing RAAS pathway activity and lowering the ACE2 levels, reducing cytokine storms, and may be beneficial in reducing mortality in ARDS related COVID-19. Further large-scale randomized clinical trials should be conducted before a definite recommendation can be drawn.
format	article
author	Mochamad Yusuf Alsagaff Eka Prasetya Budi Mulia
author_facet	Mochamad Yusuf Alsagaff Eka Prasetya Budi Mulia
author_sort	Mochamad Yusuf Alsagaff
title	Hypertension and COVID-19: Potential use of beta-blockers and a call for randomized evidence
title_short	Hypertension and COVID-19: Potential use of beta-blockers and a call for randomized evidence
title_full	Hypertension and COVID-19: Potential use of beta-blockers and a call for randomized evidence
title_fullStr	Hypertension and COVID-19: Potential use of beta-blockers and a call for randomized evidence
title_full_unstemmed	Hypertension and COVID-19: Potential use of beta-blockers and a call for randomized evidence
title_sort	hypertension and covid-19: potential use of beta-blockers and a call for randomized evidence
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/052af62d733549f38d2a5ef5588abc55
work_keys_str_mv	AT mochamadyusufalsagaff hypertensionandcovid19potentialuseofbetablockersandacallforrandomizedevidence AT ekaprasetyabudimulia hypertensionandcovid19potentialuseofbetablockersandacallforrandomizedevidence
_version_	1718400930804662272

Hypertension and COVID-19: Potential use of beta-blockers and a call for randomized evidence

Ejemplares similares